CLU and cancer: Considering the important involvement of inflammatory processes in PCa onset and progression, the pharmacological strategies aimed at counteract epigenetic CLU downregulation in early stages of PCa could be crucial for effectively controlling the signaling pathways that lead to proliferation and invasion in advanced cancers.